Management's primary operational goal for 2025 is to secure multiple licensing agreements for human diagnostic applications. In September Volition entered into two such licensing agreements The company's 1st commercial order for Nu.Q Cancer assays was received in November. The key financial goal for 2025 is to achieve cash neutrality on a full-year basis. In 3Q 2025, cash burn was reduced to 1.2 million per month. Papers, posters, conference presentations, webinars etc. continue on a brisk pace.
